Maravai LifeSciences (MRVI) Financials

$2.07 +0.04 (+1.97%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$2.06 0.00 (-0.24%)

As of 04:40 AM Eastern

Annual Income Statements for Maravai LifeSciences

This table shows Maravai LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	220	-119	-145
Consolidated Net Income / (Loss)	491	-138	-260
Net Income / (Loss) Continuing Operations	491	-138	-260
Total Pre-Tax Income	551	618	-261
Total Operating Income	574	-32	-236
Total Gross Profit	714	140	108
Total Revenue	883	289	259
Operating Revenue	883	289	259
Total Cost of Revenue	169	149	151
Operating Cost of Revenue	169	149	151
Total Operating Expenses	140	172	344
Selling, General & Admin Expense	129	151	162
Research & Development Expense	18	17	19
Impairment Charge	0.00	0.00	166
Restructuring Charge	0.00	6.47	-1.21
Other Special Charges / (Income)	-7.80	-3.29	-2.00
Total Other Income / (Expense), net	-19	649	-26
Interest Expense	21	46	51
Interest & Investment Income	2.34	28	27
Other Income / (Expense), net	-0.36	668	-2.34
Income Tax Expense	61	756	-1.86
Net Income / (Loss) Attributable to Noncontrolling Interest	270	-19	-115
Basic Earnings per Share	$1.67	($0.90)	($1.05)
Weighted Average Basic Shares Outstanding	131.55M	131.92M	137.91M
Diluted Earnings per Share	$1.67	($0.90)	($1.05)
Weighted Average Diluted Shares Outstanding	255.32M	131.92M	137.91M
Weighted Average Basic & Diluted Shares Outstanding	250.88M	251.40M	254.34M

This table shows Maravai LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	44	38	-0.07	-6.54	-6.46	-106	-12	-7.59	-99	-26
Consolidated Net Income / (Loss)	100	87	-1.35	-12	-15	-110	-23	-14	-176	-46
Net Income / (Loss) Continuing Operations	100	87	-1.35	-12	-15	-110	-23	-14	-176	-46
Total Pre-Tax Income	114	96	-4.52	-13	-21	656	-22	-17	-176	-47
Total Operating Income	117	109	2.53	-12	-15	-7.15	-19	-9.51	-169	-38
Total Gross Profit	153	151	45	26	30	39	26	35	28	19
Total Revenue	191	205	79	69	67	74	64	73	65	56
Operating Revenue	191	205	79	69	67	74	64	73	65	56
Total Cost of Revenue	38	53	34	43	37	35	38	38	37	37
Operating Cost of Revenue	38	53	34	43	37	35	38	38	37	37
Total Operating Expenses	36	42	43	37	46	46	45	45	197	57
Selling, General & Admin Expense	31	37	39	35	39	38	41	41	39	41
Research & Development Expense	5.39	5.01	4.15	4.19	4.35	4.59	5.03	5.28	4.34	4.56
Restructuring Charge	-	-	0.00	0.00	0.00	6.47	-1.21	-0.00	-0.00	0.01
Total Other Income / (Expense), net	-3.14	-9.27	-7.06	-1.75	-5.15	663	-3.55	-7.42	-6.49	-8.37
Interest Expense	3.14	10	12	7.02	12	15	11	12	14	14
Interest & Investment Income	0.00	2.34	6.05	6.79	7.43	7.46	7.21	7.09	7.07	6.04
Other Income / (Expense), net	-0.00	-1.43	-1.27	-1.52	-0.94	671	0.11	-2.56	0.07	0.04
Income Tax Expense	14	8.45	-3.18	-1.42	-5.46	766	0.27	-2.44	0.31	-0.01
Net Income / (Loss) Attributable to Noncontrolling Interest	55	50	-1.28	-5.40	-8.64	-4.02	-11	-6.91	-77	-20
Basic Earnings per Share	$0.34	$0.28	$0.00	($0.05)	($0.05)	($0.80)	($0.09)	($0.05)	($0.70)	($0.21)
Weighted Average Basic Shares Outstanding	131.54M	131.55M	131.74M	131.86M	131.93M	131.92M	132.33M	135.84M	141.56M	137.91M
Diluted Earnings per Share	$0.34	$0.30	$0.00	($0.05)	($0.05)	($0.80)	($0.09)	($0.05)	($0.70)	($0.21)
Weighted Average Diluted Shares Outstanding	131.65M	255.32M	131.74M	131.86M	131.93M	131.92M	132.33M	135.84M	141.56M	137.91M
Weighted Average Basic & Diluted Shares Outstanding	255.21M	250.88M	250.98M	251.02M	251.28M	251.40M	251.92M	252.24M	252.53M	254.34M

This table details how cash moves in and out of Maravai LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	81	-57	-253
Net Cash From Operating Activities	536	126	7.47
Net Cash From Continuing Operating Activities	536	126	7.47
Net Income / (Loss) Continuing Operations	491	-138	-260
Consolidated Net Income / (Loss)	491	-138	-260
Depreciation Expense	7.57	13	21
Amortization Expense	33	39	39
Non-Cash Adjustments To Reconcile Net Income	11	-637	222
Changes in Operating Assets and Liabilities, net	-6.46	850	-15
Net Cash From Investing Activities	-268	-122	-24
Net Cash From Continuing Investing Activities	-268	-122	-24
Purchase of Property, Plant & Equipment	-17	-66	-30
Acquisitions	-239	-70	-1.80
Divestitures	0.62	0.00	0.00
Other Investing Activities, net	-12	13	7.14
Net Cash From Financing Activities	-187	-61	-236
Net Cash From Continuing Financing Activities	-187	-61	-236
Repayment of Debt	-14	-5.44	-236
Payment of Dividends	-150	-9.61	-0.49
Issuance of Debt	8.46	0.00	0.95
Issuance of Common Equity	2.36	-0.02	-2.08
Other Financing Activities, net	-34	-46	1.55
Cash Interest Paid	20	44	51
Cash Income Taxes Paid	23	-2.99	0.67

This table details how cash moves in and out of Maravai LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	67	15	-3.87	-48	-0.57	-4.64	-13	11	4.99	-256
Net Cash From Operating Activities	110	99	85	19	14	7.79	-8.47	17	13	-15
Net Cash From Continuing Operating Activities	110	99	85	19	14	7.79	-8.47	17	13	-15
Net Income / (Loss) Continuing Operations	100	87	-1.35	-12	-15	-110	-23	-14	-176	-46
Consolidated Net Income / (Loss)	100	87	-1.35	-12	-15	-110	-23	-14	-176	-46
Depreciation Expense	1.86	1.96	2.08	2.82	4.07	3.93	4.79	5.56	5.04	5.47
Amortization Expense	8.78	8.72	9.55	9.71	9.76	9.79	9.71	9.74	9.75	9.72
Non-Cash Adjustments To Reconcile Net Income	0.49	5.87	7.10	6.01	10	-660	12	14	169	27
Changes in Operating Assets and Liabilities, net	-0.72	-4.65	68	13	5.43	764	-13	2.97	5.66	-11
Net Cash From Investing Activities	-5.85	-19	-70	-24	-16	-13	-4.24	-6.18	-8.96	-4.93
Net Cash From Continuing Investing Activities	-5.85	-19	-70	-24	-16	-13	-4.24	-6.18	-8.96	-4.93
Purchase of Property, Plant & Equipment	-6.47	-6.21	-7.87	-25	-16	-17	-5.67	-9.55	-8.59	-5.85
Acquisitions	-	-0.13	-70	0.11	-	-	0.00	-	-1.00	-0.80
Other Investing Activities, net	-	-12	7.87	0.79	0.31	3.90	1.42	3.37	0.63	1.72
Net Cash From Financing Activities	-37	-66	-19	-43	0.78	0.47	-0.56	0.23	0.81	-236
Net Cash From Continuing Financing Activities	-37	-66	-19	-43	0.78	0.47	-0.56	0.23	0.81	-236
Repayment of Debt	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-232
Payment of Dividends	-37	-31	-8.30	-1.31	-	-	0.00	-0.57	-	0.08
Issuance of Common Equity	0.73	0.37	-0.33	0.35	0.31	-0.35	-1.43	-0.03	-0.02	-0.60
Other Financing Activities, net	-	-34	-9.21	-41	1.83	2.18	2.23	2.19	2.19	-5.06
Cash Interest Paid	5.28	8.78	9.59	11	12	12	12	12	12	15
Cash Income Taxes Paid	5.73	3.45	-0.52	0.45	-3.01	0.09	0.20	0.18	0.27	0.03

This table presents Maravai LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	2,282	1,487	1,008
Total Current Assets	848	700	429
Cash & Equivalents	632	575	322
Accounts Receivable	139	55	39
Inventories, net	43	51	50
Prepaid Expenses	26	19	18
Plant, Property, & Equipment, net	0.00	0.00	164
Total Noncurrent Assets	1,434	788	415
Goodwill	284	326	160
Intangible Assets	217	221	195
Other Noncurrent Operating Assets	168	241	60
Total Liabilities & Shareholders' Equity	2,282	1,487	1,008
Total Liabilities	1,377	698	431
Total Current Liabilities	110	87	57
Short-Term Debt	5.44	5.44	5.44
Accounts Payable	48	18	12
Accrued Expenses	53	60	36
Current Deferred Revenue	3.09	3.36	2.38
Other Current Liabilities	0.00	0.63	0.79
Total Noncurrent Liabilities	1,267	610	374
Long-Term Debt	522	519	290
Other Noncurrent Operating Liabilities	745	91	84
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	905	790	577
Total Preferred & Common Equity	545	417	325
Total Common Equity	545	417	325
Common Stock	140	131	184
Retained Earnings	405	286	141
Noncontrolling Interest	360	373	252

This table presents Maravai LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	2,249	2,315	2,264	2,268	1,445	1,448	1,278
Total Current Assets	836	766	699	701	668	685	679
Cash & Equivalents	617	628	580	580	562	573	578
Accounts Receivable	114	56	49	46	37	39	29
Inventories, net	62	55	47	49	50	49	50
Prepaid Expenses	23	26	23	23	17	17	22
Plant, Property, & Equipment, net	48	88	0.00	0.00	162	0.00	0.00
Total Noncurrent Assets	1,365	1,462	1,565	1,567	615	762	599
Goodwill	284	327	326	326	326	326	172
Intangible Assets	223	242	235	228	214	207	202
Other Noncurrent Operating Assets	87	127	234	239	75	229	225
Total Liabilities & Shareholders' Equity	2,249	2,315	2,264	2,268	1,445	1,448	1,278
Total Liabilities	1,407	1,415	1,367	1,375	667	671	665
Total Current Liabilities	116	125	75	78	59	69	63
Short-Term Debt	5.44	5.74	5.44	5.44	5.44	5.44	5.44
Accounts Payable	44	47	16	14	15	20	17
Accrued Expenses	60	70	50	56	35	41	38
Current Deferred Revenue	5.82	2.05	2.46	2.55	2.21	2.08	1.83
Other Current Liabilities	-	-	0.56	0.60	0.67	0.71	0.75
Total Noncurrent Liabilities	1,292	1,290	1,292	1,297	608	603	602
Long-Term Debt	523	521	520	520	518	517	516
Other Noncurrent Operating Liabilities	58	66	763	771	90	86	86
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	842	901	898	892	777	776	613
Total Preferred & Common Equity	504	522	521	519	411	437	345
Total Common Equity	504	522	521	519	411	437	345
Common Stock	137	117	122	128	137	171	178
Retained Earnings	367	405	398	392	274	266	167
Noncontrolling Interest	338	379	377	373	367	339	268

This table displays calculated financial ratios and metrics derived from Maravai LifeSciences' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	10.48%	-67.28%	-10.30%
EBITDA Growth	2.93%	11.85%	-125.92%
EBIT Growth	2.29%	10.81%	-137.42%
NOPAT Growth	4.19%	-98.61%	-2,426.50%
Net Income Growth	4.56%	-128.20%	-87.62%
EPS Growth	7.05%	-153.89%	-16.67%
Operating Cash Flow Growth	45.42%	-76.45%	-94.09%
Free Cash Flow Firm Growth	527.78%	-92.77%	-65.88%
Invested Capital Growth	-35.34%	-7.68%	-25.48%
Revenue Q/Q Growth	-2.62%	-31.12%	-6.40%
EBITDA Q/Q Growth	-6.53%	453.80%	-134.10%
EBIT Q/Q Growth	-7.11%	742.34%	-151.26%
NOPAT Q/Q Growth	-6.66%	-91.86%	-210.06%
Net Income Q/Q Growth	-7.48%	-334.39%	19.65%
EPS Q/Q Growth	-7.73%	-550.00%	35.98%
Operating Cash Flow Q/Q Growth	8.19%	-42.04%	-75.03%
Free Cash Flow Firm Q/Q Growth	195.96%	-90.39%	-94.57%
Invested Capital Q/Q Growth	-45.31%	-11.77%	-1.07%
Profitability Metrics	-	-	-
Gross Margin	80.87%	48.52%	41.79%
EBITDA Margin	69.62%	237.97%	-68.75%
Operating Margin	65.03%	-10.95%	-90.91%
EBIT Margin	64.99%	220.08%	-91.81%
Profit (Net Income) Margin	55.57%	-47.89%	-100.17%
Tax Burden Percent	88.97%	-22.40%	99.29%
Interest Burden Percent	96.10%	97.14%	109.89%
Effective Tax Rate	11.03%	122.40%	0.00%
Return on Invested Capital (ROIC)	50.12%	0.92%	-25.57%
ROIC Less NNEP Spread (ROIC-NNEP)	43.24%	187.99%	219.48%
Return on Net Nonoperating Assets (RNNOA)	17.53%	-17.25%	-12.41%
Return on Equity (ROE)	67.65%	-16.33%	-37.98%
Cash Return on Invested Capital (CROIC)	93.05%	8.91%	3.63%
Operating Return on Assets (OROA)	27.32%	33.74%	-19.07%
Return on Assets (ROA)	23.36%	-7.34%	-20.81%
Return on Common Equity (ROCE)	40.14%	-9.27%	-20.62%
Return on Equity Simple (ROE_SIMPLE)	89.99%	-33.20%	-79.81%
Net Operating Profit after Tax (NOPAT)	511	7.09	-165
NOPAT Margin	57.86%	2.45%	-63.63%
Net Nonoperating Expense Percent (NNEP)	6.88%	-187.07%	-245.05%
Return On Investment Capital (ROIC_SIMPLE)	35.66%	0.54%	-18.89%
Cost of Revenue to Revenue	19.13%	51.48%	58.21%
SG&A Expenses to Revenue	14.64%	52.39%	62.42%
R&D to Revenue	2.08%	5.98%	7.42%
Operating Expenses to Revenue	15.84%	59.48%	132.70%
Earnings before Interest and Taxes (EBIT)	574	636	-238
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	615	688	-178
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	6.70	3.95	4.23
Price to Tangible Book Value (P/TBV)	81.36	0.00	0.00
Price to Revenue (P/Rev)	4.14	5.70	5.31
Price to Earnings (P/E)	16.58	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	6.03%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.88	2.66	2.91
Enterprise Value to Revenue (EV/Rev)	4.43	6.81	6.18
Enterprise Value to EBITDA (EV/EBITDA)	6.36	2.86	0.00
Enterprise Value to EBIT (EV/EBIT)	6.81	3.10	0.00
Enterprise Value to NOPAT (EV/NOPAT)	7.65	277.63	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.29	15.59	214.56
Enterprise Value to Free Cash Flow (EV/FCFF)	4.12	28.71	68.46
Leverage & Solvency	-	-	-
Debt to Equity	0.58	0.66	0.51
Long-Term Debt to Equity	0.58	0.66	0.50
Financial Leverage	0.41	-0.09	-0.06
Leverage Ratio	2.90	2.22	1.83
Compound Leverage Factor	2.78	2.16	2.01
Debt to Total Capital	36.81%	39.89%	33.89%
Short-Term Debt to Total Capital	0.38%	0.41%	0.62%
Long-Term Debt to Total Capital	36.44%	39.47%	33.27%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	25.13%	28.40%	28.85%
Common Equity to Total Capital	38.06%	31.72%	37.26%
Debt to EBITDA	0.86	0.76	-1.66
Net Debt to EBITDA	-0.17	-0.07	0.15
Long-Term Debt to EBITDA	0.85	0.75	-1.63
Debt to NOPAT	1.03	73.94	-1.79
Net Debt to NOPAT	-0.20	-7.17	0.16
Long-Term Debt to NOPAT	1.02	73.17	-1.76
Altman Z-Score	3.44	3.78	2.03
Noncontrolling Interest Sharing Ratio	40.66%	43.25%	45.72%
Liquidity Ratios	-	-	-
Current Ratio	7.70	8.00	7.53
Quick Ratio	7.00	7.20	6.34
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	949	69	23
Operating Cash Flow to CapEx	3,136.20%	192.55%	25.17%
Free Cash Flow to Firm to Interest Expense	46.00	1.49	0.46
Operating Cash Flow to Interest Expense	25.99	2.75	0.15
Operating Cash Flow Less CapEx to Interest Expense	25.16	1.32	-0.44
Efficiency Ratios	-	-	-
Asset Turnover	0.42	0.15	0.21
Accounts Receivable Turnover	6.89	2.99	5.57
Inventory Turnover	3.57	3.15	2.97
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	3.70	4.50	10.14
Days Sales Outstanding (DSO)	52.94	122.05	65.57
Days Inventory Outstanding (DIO)	102.30	116.01	122.75
Days Payable Outstanding (DPO)	98.55	81.03	35.99
Cash Conversion Cycle (CCC)	56.69	157.02	152.33
Capital & Investment Metrics	-	-	-
Invested Capital	801	739	551
Invested Capital Turnover	0.87	0.38	0.40
Increase / (Decrease) in Invested Capital	-438	-61	-188
Enterprise Value (EV)	3,907	1,968	1,602
Market Capitalization	3,652	1,646	1,376
Book Value per Share	$2.14	$1.66	$1.29
Tangible Book Value per Share	$0.18	($0.52)	($0.12)
Total Capital	1,433	1,314	873
Total Debt	527	524	296
Total Long-Term Debt	522	519	290
Net Debt	-105	-51	-26
Capital Expenditures (CapEx)	17	66	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	111	43	55
Debt-free Net Working Capital (DFNWC)	743	618	378
Net Working Capital (NWC)	738	612	372
Net Nonoperating Expense (NNE)	20	145	95
Net Nonoperating Obligations (NNO)	-105	-51	-26
Total Depreciation and Amortization (D&A)	41	52	60
Debt-free, Cash-free Net Working Capital to Revenue	12.58%	14.85%	21.30%
Debt-free Net Working Capital to Revenue	84.17%	213.84%	145.69%
Net Working Capital to Revenue	83.55%	211.96%	143.59%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.67	($0.90)	($1.05)
Adjusted Weighted Average Basic Shares Outstanding	131.55M	131.92M	137.91M
Adjusted Diluted Earnings per Share	$1.67	($0.90)	($1.05)
Adjusted Weighted Average Diluted Shares Outstanding	255.32M	131.92M	137.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	250.88M	251.40M	254.34M
Normalized Net Operating Profit after Tax (NOPAT)	504	-20	-51
Normalized NOPAT Margin	57.07%	-6.90%	-19.63%
Pre Tax Income Margin	62.45%	213.79%	-100.89%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	27.83	13.86	-4.68
NOPAT to Interest Expense	24.77	0.15	-3.24
EBIT Less CapEx to Interest Expense	27.00	12.43	-5.26
NOPAT Less CapEx to Interest Expense	23.95	-1.27	-3.82
Payout Ratios	-	-	-
Dividend Payout Ratio	30.61%	-6.94%	-0.19%
Augmented Payout Ratio	30.61%	-6.94%	-0.19%

This table displays calculated financial ratios and metrics derived from Maravai LifeSciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.61%	-10.39%	-67.65%	-71.61%	-65.04%	-63.78%	-18.79%	6.51%	-2.49%	-23.92%
EBITDA Growth	-25.37%	-26.61%	-92.83%	-100.32%	-101.98%	472.01%	-133.06%	630.86%	-6,011.29%	-103.38%
EBIT Growth	-26.34%	-28.93%	-99.25%	-107.32%	-113.99%	515.96%	-1,582.61%	8.06%	-933.39%	-105.73%
NOPAT Growth	-24.70%	-26.62%	-98.80%	-105.02%	-110.54%	-98.80%	-844.61%	18.10%	-996.93%	-2,327.23%
Net Income Growth	-24.61%	-31.22%	-100.92%	-107.62%	-115.15%	-225.80%	-1,582.49%	-21.34%	-1,065.11%	57.72%
EPS Growth	-22.73%	-31.82%	-100.00%	-109.43%	-114.71%	-366.67%	0.00%	0.00%	-1,300.00%	73.75%
Operating Cash Flow Growth	4.26%	69.10%	-47.58%	-88.32%	-87.13%	-92.16%	-109.95%	-9.17%	-7.27%	-287.91%
Free Cash Flow Firm Growth	88.70%	363.99%	92.83%	275.66%	594.47%	-88.33%	2,799.44%	-81.90%	-73.58%	157.91%
Invested Capital Growth	18.34%	-35.34%	2.00%	-42.38%	-42.77%	-7.68%	-50.51%	-13.93%	-33.54%	-25.48%
Revenue Q/Q Growth	-21.20%	7.03%	-61.40%	-12.79%	-2.97%	10.88%	-13.44%	14.37%	-11.17%	-13.49%
EBITDA Q/Q Growth	-32.54%	-7.08%	-88.73%	-104.70%	-316.50%	26,956.18%	-100.63%	175.48%	-4,894.81%	85.15%
EBIT Q/Q Growth	-34.85%	-7.77%	-98.78%	-1,138.18%	-24.56%	4,159.95%	-102.82%	35.62%	-1,300.05%	77.47%
NOPAT Q/Q Growth	-36.72%	-2.72%	-98.22%	-558.51%	-32.75%	111.10%	-1,201.70%	49.57%	-1,677.90%	77.45%
Net Income Q/Q Growth	-36.41%	-12.27%	-101.54%	-785.98%	-26.45%	-628.26%	79.38%	36.10%	-1,114.15%	73.58%
EPS Q/Q Growth	-35.85%	-11.76%	-100.00%	0.00%	0.00%	-1,500.00%	88.75%	44.44%	-1,300.00%	70.00%
Operating Cash Flow Q/Q Growth	-33.00%	-9.74%	-14.36%	-77.44%	-26.20%	-45.01%	-208.69%	305.91%	-24.65%	-211.43%
Free Cash Flow Firm Q/Q Growth	64.29%	531.74%	-105.11%	2,329.79%	0.53%	-89.81%	1,082.35%	-85.05%	46.70%	-0.57%
Invested Capital Q/Q Growth	0.02%	-45.31%	86.53%	-43.53%	-0.66%	-11.77%	-0.01%	-1.79%	-23.30%	-1.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.04%	73.99%	57.39%	37.21%	45.13%	52.65%	40.27%	47.86%	43.52%	33.62%
EBITDA Margin	66.68%	57.89%	16.31%	-0.88%	-3.77%	914.27%	-6.64%	4.38%	-236.58%	-40.60%
Operating Margin	61.12%	53.37%	3.21%	-16.85%	-23.06%	-9.64%	-29.39%	-12.96%	-259.38%	-67.60%
EBIT Margin	61.12%	52.67%	1.60%	-19.06%	-24.46%	895.76%	-29.22%	-16.45%	-259.27%	-67.52%
Profit (Net Income) Margin	52.10%	42.71%	-1.71%	-17.33%	-22.59%	-148.34%	-35.34%	-19.74%	-269.87%	-82.43%
Tax Burden Percent	87.60%	91.19%	29.80%	89.37%	73.44%	-16.76%	101.21%	85.61%	100.18%	99.98%
Interest Burden Percent	97.32%	88.92%	-357.55%	101.76%	125.71%	98.80%	119.48%	140.19%	103.91%	122.09%
Effective Tax Rate	12.40%	8.81%	0.00%	0.00%	0.00%	116.76%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	35.95%	42.15%	1.09%	-5.56%	-5.88%	0.61%	-5.05%	-3.22%	-72.12%	-19.02%
ROIC Less NNEP Spread (ROIC-NNEP)	35.56%	38.01%	0.64%	-6.76%	-7.40%	143.59%	-8.47%	11.69%	31.55%	32.23%
Return on Net Nonoperating Assets (RNNOA)	38.58%	15.41%	0.58%	-2.57%	-2.42%	-13.17%	-2.80%	-0.73%	-2.33%	-1.82%
Return on Equity (ROE)	74.54%	57.56%	1.67%	-8.13%	-8.31%	-12.57%	-7.85%	-3.96%	-74.45%	-20.84%
Cash Return on Invested Capital (CROIC)	23.73%	93.05%	22.97%	70.83%	61.98%	8.91%	68.84%	16.74%	61.79%	3.63%
Operating Return on Assets (OROA)	26.75%	22.14%	0.53%	-4.67%	-4.54%	137.32%	-4.26%	-2.47%	-40.50%	-14.02%
Return on Assets (ROA)	22.80%	17.96%	-0.56%	-4.25%	-4.20%	-22.74%	-5.15%	-2.96%	-42.15%	-17.12%
Return on Common Equity (ROCE)	46.40%	34.16%	0.97%	-4.76%	-4.90%	-7.13%	-4.36%	-2.26%	-42.75%	-11.31%
Return on Equity Simple (ROE_SIMPLE)	105.28%	0.00%	65.67%	33.38%	11.37%	0.00%	-38.89%	-37.14%	-93.62%	0.00%
Net Operating Profit after Tax (NOPAT)	102	100	1.77	-8.13	-11	1.20	-13	-6.66	-118	-27
NOPAT Margin	53.54%	48.66%	2.24%	-11.80%	-16.14%	1.62%	-20.57%	-9.07%	-181.56%	-47.32%
Net Nonoperating Expense Percent (NNEP)	0.39%	4.15%	0.45%	1.20%	1.52%	-142.98%	3.42%	-14.91%	-103.67%	-51.25%
Return On Investment Capital (ROIC_SIMPLE)	-	6.95%	-	-	-	0.09%	-	-	-	-3.06%
Cost of Revenue to Revenue	19.96%	26.01%	42.61%	62.79%	54.87%	47.35%	59.73%	52.14%	56.48%	66.38%
SG&A Expenses to Revenue	16.10%	18.17%	48.94%	51.34%	58.12%	51.90%	63.70%	55.25%	59.95%	73.12%
R&D to Revenue	2.82%	2.45%	5.25%	6.09%	6.50%	6.20%	7.84%	7.20%	6.66%	8.09%
Operating Expenses to Revenue	18.92%	20.62%	54.18%	54.06%	68.19%	62.29%	69.66%	60.82%	302.90%	101.22%
Earnings before Interest and Taxes (EBIT)	117	108	1.27	-13	-16	664	-19	-12	-169	-38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	128	119	13	-0.61	-2.52	678	-4.26	3.22	-154	-23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.93	6.70	6.74	5.99	4.83	3.95	5.31	4.13	6.07	4.23
Price to Tangible Book Value (P/TBV)	0.00	81.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	7.19	4.14	4.90	5.74	5.98	5.70	7.95	6.47	7.57	5.31
Price to Earnings (P/E)	27.33	16.58	22.93	41.32	102.19	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.66%	6.03%	4.36%	2.42%	0.98%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.62	4.88	2.55	4.08	3.38	2.66	3.39	2.88	4.15	2.91
Enterprise Value to Revenue (EV/Rev)	7.46	4.43	5.31	6.33	6.74	6.81	9.15	7.51	8.33	6.18
Enterprise Value to EBITDA (EV/EBITDA)	10.28	6.36	8.58	13.54	22.78	2.86	3.74	3.10	4.42	0.00
Enterprise Value to EBIT (EV/EBIT)	10.95	6.81	9.49	16.49	37.47	3.10	4.07	3.39	4.97	0.00
Enterprise Value to NOPAT (EV/NOPAT)	12.36	7.65	10.33	17.50	32.47	277.63	177.59	150.97	15.40	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	13.65	7.29	8.30	10.97	12.99	15.59	76.74	67.67	77.20	214.56
Enterprise Value to Free Cash Flow (EV/FCFF)	21.11	4.12	11.22	4.21	3.97	28.71	3.26	15.93	5.36	68.46
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.63	0.58	0.60	0.59	0.59	0.66	0.67	0.67	0.85	0.51
Long-Term Debt to Equity	0.62	0.58	0.60	0.58	0.58	0.66	0.67	0.67	0.84	0.50
Financial Leverage	1.08	0.41	0.90	0.38	0.33	-0.09	0.33	-0.06	-0.07	-0.06
Leverage Ratio	3.20	2.90	2.80	2.65	2.60	2.22	2.24	2.22	2.36	1.83
Compound Leverage Factor	3.11	2.58	-10.02	2.70	3.27	2.20	2.68	3.11	2.45	2.23
Debt to Total Capital	38.56%	36.81%	37.63%	36.94%	37.04%	39.89%	40.23%	40.23%	45.97%	33.89%
Short-Term Debt to Total Capital	0.40%	0.38%	0.40%	0.38%	0.38%	0.41%	0.42%	0.42%	0.48%	0.62%
Long-Term Debt to Total Capital	38.16%	36.44%	37.24%	36.56%	36.66%	39.47%	39.82%	39.81%	45.49%	33.27%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	24.67%	25.13%	26.25%	26.49%	26.32%	28.40%	28.19%	26.14%	23.61%	28.85%
Common Equity to Total Capital	36.77%	38.06%	36.11%	36.57%	36.64%	31.72%	31.57%	33.64%	30.41%	37.26%
Debt to EBITDA	0.80	0.86	1.22	2.07	4.23	0.76	0.78	0.77	1.00	-1.66
Net Debt to EBITDA	-0.14	-0.17	-0.19	-0.21	-0.44	-0.07	-0.06	-0.08	-0.11	0.15
Long-Term Debt to EBITDA	0.79	0.85	1.21	2.05	4.18	0.75	0.77	0.77	0.99	-1.63
Debt to NOPAT	0.97	1.03	1.47	2.67	6.03	73.94	37.06	37.70	3.48	-1.79
Net Debt to NOPAT	-0.16	-0.20	-0.23	-0.28	-0.63	-7.17	-2.72	-3.65	-0.38	0.16
Long-Term Debt to NOPAT	0.96	1.02	1.46	2.64	5.96	73.17	36.67	37.30	3.45	-1.76
Altman Z-Score	3.97	2.77	2.38	2.17	1.83	3.85	2.88	2.55	2.43	2.69
Noncontrolling Interest Sharing Ratio	37.74%	40.66%	41.86%	41.54%	41.00%	43.25%	44.45%	42.80%	42.58%	45.72%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.22	7.70	6.13	9.33	8.96	8.00	11.32	10.00	10.74	7.53
Quick Ratio	6.33	7.00	5.48	8.40	7.99	7.20	10.14	8.92	9.60	6.34
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-124	537	-27	612	615	63	741	111	163	162
Operating Cash Flow to CapEx	1,701.86%	1,598.57%	1,081.27%	76.60%	89.51%	46.37%	-149.46%	182.50%	152.90%	-250.27%
Free Cash Flow to Firm to Interest Expense	-39.68	52.77	-2.32	87.17	52.87	4.07	68.21	9.28	11.92	11.19
Operating Cash Flow to Interest Expense	35.10	9.76	7.19	2.73	1.22	0.51	-0.78	1.46	0.96	-1.01
Operating Cash Flow Less CapEx to Interest Expense	33.03	9.15	6.52	-0.84	-0.14	-0.59	-1.30	0.66	0.33	-1.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.44	0.42	0.33	0.25	0.19	0.15	0.15	0.15	0.16	0.21
Accounts Receivable Turnover	10.07	6.89	8.13	6.42	5.25	2.99	5.90	6.36	7.43	5.57
Inventory Turnover	2.61	3.57	3.06	3.13	2.99	3.15	2.93	3.07	2.98	2.97
Fixed Asset Turnover	11.57	0.00	10.60	0.00	0.00	0.00	2.20	0.00	0.00	0.00
Accounts Payable Turnover	5.69	3.70	3.53	4.54	5.77	4.50	4.92	8.31	9.79	10.14
Days Sales Outstanding (DSO)	36.23	52.94	44.91	56.82	69.49	122.05	61.89	57.41	49.13	65.57
Days Inventory Outstanding (DIO)	139.87	102.30	119.23	116.53	122.00	116.01	124.52	118.92	122.31	122.75
Days Payable Outstanding (DPO)	64.14	98.55	103.45	80.35	63.24	81.03	74.16	43.93	37.28	35.99
Cash Conversion Cycle (CCC)	111.96	56.69	60.69	93.00	128.26	157.02	112.25	132.40	134.16	152.33
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,464	801	1,493	843	838	739	739	726	557	551
Invested Capital Turnover	0.67	0.87	0.49	0.47	0.36	0.38	0.25	0.36	0.40	0.40
Increase / (Decrease) in Invested Capital	227	-438	29	-620	-626	-61	-754	-117	-281	-188
Enterprise Value (EV)	6,764	3,907	3,809	3,442	2,829	1,968	2,508	2,093	2,308	1,602
Market Capitalization	6,515	3,652	3,515	3,120	2,510	1,646	2,180	1,804	2,096	1,376
Book Value per Share	$1.97	$2.14	$2.08	$2.07	$2.07	$1.66	$1.63	$1.73	$1.37	$1.29
Tangible Book Value per Share	($0.01)	$0.18	($0.19)	($0.16)	($0.14)	($0.52)	($0.52)	($0.38)	($0.11)	($0.12)
Total Capital	1,370	1,433	1,444	1,423	1,417	1,314	1,301	1,299	1,135	873
Total Debt	528	527	543	526	525	524	523	523	522	296
Total Long-Term Debt	523	522	538	520	520	519	518	517	516	290
Net Debt	-89	-105	-85	-54	-55	-51	-38	-51	-56	-26
Capital Expenditures (CapEx)	6.47	6.21	7.87	25	16	17	5.67	9.55	8.59	5.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)	108	111	18	50	48	43	53	49	43	55
Debt-free Net Working Capital (DFNWC)	725	743	646	630	628	618	614	622	621	378
Net Working Capital (NWC)	720	738	641	624	623	612	609	617	616	372
Net Nonoperating Expense (NNE)	2.75	12	3.12	3.81	4.31	111	9.48	7.83	58	20
Net Nonoperating Obligations (NNO)	622	-105	593	-54	-55	-51	-38	-51	-56	-26
Total Depreciation and Amortization (D&A)	11	11	12	13	14	14	14	15	15	15
Debt-free, Cash-free Net Working Capital to Revenue	11.90%	12.58%	2.52%	9.13%	11.55%	14.85%	19.19%	17.62%	15.58%	21.30%
Debt-free Net Working Capital to Revenue	79.99%	84.17%	90.06%	115.80%	149.71%	213.84%	224.12%	223.36%	224.36%	145.69%
Net Working Capital to Revenue	79.39%	83.55%	89.26%	114.80%	148.41%	211.96%	222.13%	221.41%	222.40%	143.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.34	$0.28	$0.00	($0.05)	($0.05)	($0.80)	($0.09)	($0.05)	($0.70)	($0.21)
Adjusted Weighted Average Basic Shares Outstanding	131.54M	131.55M	131.74M	131.86M	131.93M	131.92M	132.33M	135.84M	141.56M	137.91M
Adjusted Diluted Earnings per Share	$0.34	$0.30	$0.00	($0.05)	($0.05)	($0.80)	($0.09)	($0.05)	($0.70)	($0.21)
Adjusted Weighted Average Diluted Shares Outstanding	131.65M	255.32M	131.74M	131.86M	131.93M	131.92M	132.33M	135.84M	141.56M	137.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	255.21M	250.88M	250.98M	251.02M	251.28M	251.40M	251.92M	252.24M	252.53M	254.34M
Normalized Net Operating Profit after Tax (NOPAT)	102	100	1.77	-9.75	-9.12	-0.48	-14	-7.50	-11	-27
Normalized NOPAT Margin	53.54%	48.66%	2.24%	-14.15%	-13.64%	-0.65%	-21.89%	-10.21%	-16.17%	-47.31%
Pre Tax Income Margin	59.48%	46.83%	-5.72%	-19.39%	-30.75%	885.05%	-34.92%	-23.06%	-269.39%	-82.44%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	37.28	10.59	0.11	-1.87	-1.41	43.13	-1.73	-1.01	-12.40	-2.64
NOPAT to Interest Expense	32.65	9.79	0.15	-1.16	-0.93	0.08	-1.22	-0.56	-8.68	-1.85
EBIT Less CapEx to Interest Expense	35.21	9.98	-0.56	-5.44	-2.77	42.03	-2.25	-1.81	-13.03	-3.04
NOPAT Less CapEx to Interest Expense	30.59	9.18	-0.52	-4.73	-2.29	-1.01	-1.74	-1.36	-9.31	-2.25
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	31.38%	30.61%	34.64%	44.50%	68.64%	-6.94%	-0.82%	-0.35%	-0.18%	-0.19%
Augmented Payout Ratio	31.38%	30.61%	34.64%	44.50%	68.64%	-6.94%	-0.82%	-0.35%	-0.18%	-0.19%

Frequently Asked Questions About Maravai LifeSciences' Financials

When does Maravai LifeSciences's financial year end?

According to the most recent income statement we have on file, Maravai LifeSciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Maravai LifeSciences' net income changed over the last 2 years?

Maravai LifeSciences' net income appears to be on a downward trend, with a most recent value of -$259.62 million in 2024, falling from $490.66 million in 2022. The previous period was -$138.38 million in 2023. See where experts think Maravai LifeSciences is headed by visiting Maravai LifeSciences' forecast page.

What is Maravai LifeSciences's operating income?

Maravai LifeSciences's total operating income in 2024 was -$235.62 million, based on the following breakdown:

Total Gross Profit: $108.31 million
Total Operating Expenses: $343.93 million

How has Maravai LifeSciences revenue changed over the last 2 years?

Over the last 2 years, Maravai LifeSciences' total revenue changed from $883.00 million in 2022 to $259.19 million in 2024, a change of -70.6%.

How much debt does Maravai LifeSciences have?

Maravai LifeSciences' total liabilities were at $431.04 million at the end of 2024, a 38.2% decrease from 2023, and a 68.7% decrease since 2022.

How much cash does Maravai LifeSciences have?

In the past 2 years, Maravai LifeSciences' cash and equivalents has ranged from $322.40 million in 2024 to $632.14 million in 2022, and is currently $322.40 million as of their latest financial filing in 2024.

How has Maravai LifeSciences' book value per share changed over the last 2 years?

Over the last 2 years, Maravai LifeSciences' book value per share changed from 2.14 in 2022 to 1.29 in 2024, a change of -39.7%.

Related Companies

This page (NASDAQ:MRVI) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Financials

Frequently Asked Questions About Maravai LifeSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Financials

Annual Income Statements for Maravai LifeSciences

Quarterly Income Statements for Maravai LifeSciences

Annual Cash Flow Statements for Maravai LifeSciences

Quarterly Cash Flow Statements for Maravai LifeSciences

Annual Balance Sheets for Maravai LifeSciences

Quarterly Balance Sheets for Maravai LifeSciences

Annual Metrics and Ratios for Maravai LifeSciences

Quarterly Metrics and Ratios for Maravai LifeSciences

Frequently Asked Questions About Maravai LifeSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools